You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 357 TAK-573, an anti-CD38–attenuated interferon alpha (IFNα) fusion protein (Attenukine™), has demonstrated IFNα receptor (IFNAR) pathway modulation in patients with relapsed/refractory multiple myeloma

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
357 TAK-573, an anti-CD38–attenuated interferon alpha (IFNα) fusion protein (Attenukine™), has demonstrated IFNα receptor (IFNAR) pathway modulation in patients with relapsed/refractory multiple myeloma

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020137025
Dec 202044014
Jan 20212309
Feb 20218008
Mar 2021100019
Apr 202186011
May 202151014
Jun 20210019
Jul 20210029
Aug 20210020
Sep 20210017
Oct 2021198048
Nov 2021200045
Dec 2021212029
Jan 2022194035
Feb 2022138022
Mar 2022244044
Apr 2022208023
May 2022264030
Jun 2022280032
Jul 2022236016
Aug 2022180022
Sep 2022202014
Oct 2022226023
Nov 2022192015
Dec 2022232017
Jan 2023224019
Feb 2023288022
Mar 2023218013
Apr 2023188024
May 2023270028
Jun 202319009
Jul 2023152012
Aug 2023176011
Sep 2023128018
Oct 2023140010
Nov 2023164017
Dec 2023114011
Jan 20243204
Feb 202412408
Mar 202415006
Apr 202411206
May 202414207
Jun 20249205
Jul 20248203
Aug 20248806
Sep 2024110010
Oct 2024116015
Nov 2024116013
Dec 2024137010
Jan 202512008
Feb 20254003
Mar 2025004
Apr 2025007
May 2025004
Jun 2025204
Total74420917